Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538980 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Polycythemia Vera
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00538980 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 10 participants.
The verdict
NCT00538980, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04-30 |
| Est. Completion | 2010-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538980
The ClinicalTrials.gov registry entry for NCT00538980 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00538980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00538980 about?
NCT00538980 is a clinical study titled "Dasatinib in Polycythemia Vera". The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
What is the current status of trial NCT00538980?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-04-30. Estimated completion is 2010-08-27.
What interventions are being tested in trial NCT00538980?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00538980?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.